Abstract 1916P
Background
Dual ICI therapy is the standard of care for first-line PM patients (pts); single agent ICI improved survival vs placebo in pretreated pts. However, ICI efficacy is comprehensively unsatisfactory in PM, and no biomarkers predict response to therapy. We aimed to identify tumor features correlated with ICI efficacy in PM pts.
Methods
The NIBIT-EPI-MESO is a multicenter study led by the NIBIT Foundation in ICI-treated PM pts. Pts with irPR or irSD were classified as responders (R), those with irPD as non-responders (NR). Tumor biopsies underwent multi-omics analyses: RNA-seq, WES, RRBS, and multiplex immunofluorescence (mIF). Results were correlated with clinical outcome.
Results
Among 73 pts studied 54 had epithelioid, 16 biphasic, and 3 sarcomatoid PM; 64 received ICI as second/third line: 27 tremelimumab plus durvalumab (Calabrò, TLRM 2018), 36 nivolumab plus ipilimumab (Italian expanded access), 10 tremelimumab monotherapy (Calabrò, TLRM 2015). IrPR, irSD, and irPD were achieved by 27%, 36% and 37% of pts. Methylation profiling clustered pts into four subtypes: Demethylated, Low, Intermediate, and CIMP (hypermethylated). The Low cluster was enriched in R pts (22/41; p=0.01) who had the highest mOS (970 days), whereas the CIMP cluster was enriched in NR pts who had the worst mOS (288 days). Also, the Low cluster was the most predictive of ICI outcome in a multivariate model including sex, age, TMB, INFg gene expression (HR=0.1, CI: 0.02-0.47; p=0.003). An enriched proliferation and mitochondrial metabolism characterized the CIMP cluster, while the Low cluster was enriched in pathways associated with innate/adaptive immune response. The Low cluster had higher densities of tumor-associated CD8+ T (p=0.032) and CD20+ B cells (p=0.01) by mIF, compared to CIMP tumors. Tumor and stroma CD20+ B cells associated with response (p=0.016 and p=0.043), tumor CD4+ (p=0.009), CD8+ (p=0.01), CD68+(p=0.017) associated with OS. The low mutational rate identified did not associate with ICI response or OS.
Conclusions
Tumor methylation drives efficacy of ICI therapy in PM pts by shaping tumor immune contextures, regardless of PM histology and TMB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AIRC Foundation (ID.21073); Ministry of Health, Lombardy and Tuscany regions (NET-2016-02361632).
Disclosure
L. Calabro: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Roche, Merck Sharp Dohme; Financial Interests, Personal, Financially compensated role: Bristol Myers Squibb, AstraZeneca, Sanofi. F.P. Caruso, T. Noviello: Other, Personal, Stocks/Shares: Immunomics. A. Covre, S. Coral: Other, Personal, Stocks/Shares: Epigen Therapeutics. F. Grosso: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Novocure, Novartis, Pierre Fabre, Merck Sharp Dohme, PharmaMar. A.M. Di Giacomo: Financial Interests, Personal, Advisory Board: Pierre Fabre, GSK, Bristol Myers Squibb, Merck Sharp Dohme, Sunpharma, Immunocore, Sanofi; Financial Interests, Personal, Financially compensated role: Bristol Myers Squibb, Merck Sharp Dohme, Pierre Fabre, Sanofi. M. Ceccarelli: Other, Personal, Stocks/Shares: Immunomics; Financial Interests, Personal, Speaker, Consultant, Advisor: Moderna Therapeutics. M. Maio: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Pierre Fabre, Merck Serono, Amgen, Eli Lilly, Roche, Merck Sharp Dohme, Incyte, AstraZeneca, GSK, Sciclone, Sanofi, Alfasigma; Other, Personal, Stocks/Shares: Epigen Therapeutics, Theravance. All other authors have declared no conflicts of interest.
Resources from the same session
1455P - Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial
Presenter: Pengfei Zhang
Session: Poster session 18
Resources:
Abstract
1456P - First in human phase I/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric/gastroesophageal junction cancer
Presenter: Tianshu Liu
Session: Poster session 18
1457P - Tumor immune microenvironment subtypes of esophageal squamous cell carcinoma and their strong ability to predict the efficacy of neoadjuvant immunotherapy
Presenter: Guangyu Yao
Session: Poster session 18
1458P - Impact of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) on staging and treatment in patients with gastric cancer
Presenter: Shunyu Zhang
Session: Poster session 18
Resources:
Abstract
1459P - Long-term management and outcomes in gastroesophageal cancer in Norway
Presenter: Aleksander Kolstad
Session: Poster session 18
1460P - Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic esophagogastric cancer
Presenter: Denice Kamp
Session: Poster session 18
1462P - A pilot study of hypoxia as a potential resistance mechanism to PD-1 checkpoint blockade therapy in neoadjuvant treatment of esophageal squamous cell carcinoma (HYPERION)
Presenter: Bin Li
Session: Poster session 18
1463P - The presence of liver metastases is associated with systemic immune suppression in gastroesophageal cancer
Presenter: Sebastiaan Siegerink
Session: Poster session 18
1464P - Chemo-radiation alone associated with higher risk of death compared to chemo-radiation plus surgery in esophageal squamous cell carcinoma
Presenter: Brian Housman
Session: Poster session 18